Literature DB >> 7745683

Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells.

R Hrdlicková1, J Nehyba, H R Bose.   

Abstract

The c-rel proto-oncogene encodes a member of the Rel/NF-kappa B family of transcription factors. The oncogenic viral form, v-rel, transduced by avian reticuloendotheliosis virus T, induces lymphoid tumors. v-Rel transformation may be mediated directly by binding of v-Rel to cognate DNA sites, resulting in altered gene expression, and/or indirectly by releasing Rel/NF-kappa B transcription factors from cytoplasmic retention molecules, resulting in their translocation to the nucleus and the inappropriate expression of genes under kappa B control. v-Rel-transformed cell lines of different phenotypes contained v-Rel as well as endogenous kappa B DNA-binding proteins in nuclear extracts. Kinetic analysis with avian leukosis virus-transformed B-cell lines expressing v-Rel or c-Rel indicated that the presence of endogenous kappa B DNA-binding proteins in the nucleus is temporally correlated with the relocalization of v-Rel to the cytoplasm. Supershift analysis of these DNA-binding complexes revealed that v-Rel was present in all of the nuclear DNA-binding complexes heterodimerized with c-Rel, NF-kappa B1, and other proteins. In contrast, c-Rel-transformed cells exhibited a less-complex pattern of nuclear kappa B DNA-binding complexes, and the nuclear appearance of these endogenous complexes was not observed. Studies with c-/v-Rel hybrids suggest that the induction of the endogenous kappa B DNA-binding complexes is the result of the mutations in the C-terminal region of the Rel homology (RH) domain of v-Rel. Moreover, v-Rel differed from c-Rel in its DNA-binding specificity. The altered DNA-binding specificity of v-Rel was associated with mutations located in the N-terminal part of the RH domain of v-Rel. These results suggest that two different regions of v-Rel (both located in the RH domain) influence the formation of kappa B DNA-binding complexes differently.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745683      PMCID: PMC189049          DOI: 10.1128/JVI.69.6.3369-3380.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal.

Authors:  S Ghosh; A M Gifford; L R Riviere; P Tempst; G P Nolan; D Baltimore
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

2.  Identification of protein complexes containing the c-rel proto-oncogene product in avian hematopoietic cells.

Authors:  J N Davis; W Bargmann; H R Bose
Journal:  Oncogene       Date:  1990-08       Impact factor: 9.867

3.  The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.

Authors:  M Kieran; V Blank; F Logeat; J Vandekerckhove; F Lottspeich; O Le Bail; M B Urban; P Kourilsky; P A Baeuerle; A Israël
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

4.  Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.

Authors:  L E Morrison; G Boehmelt; P J Enrietto
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

5.  Interaction of the v-rel protein with an NF-kappa B DNA binding site.

Authors:  N Kabrun; J W Hodgson; M Doemer; G Mak; B R Franza; P J Enrietto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  Viral rel and cellular rel associate with cellular proteins in transformed and normal cells.

Authors:  L E Morrison; N Kabrun; S Mudri; M J Hayman; P J Enrietto
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

7.  Tumor necrosis factor-alpha activation of the IL-2 receptor-alpha gene involves the induction of kappa B-specific DNA binding proteins.

Authors:  J W Lowenthal; D W Ballard; H Bogerd; E Böhnlein; W C Greene
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

8.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

Authors:  E Schreiber; P Matthias; M M Müller; W Schaffner
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

9.  A recombinant murine retrovirus expressing v-rel is cytopathic.

Authors:  R C Schwartz; O N Witte
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

10.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

View more
  5 in total

1.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Loss of IkappaB alpha-mediated control over nuclear import and DNA binding enables oncogenic activation of c-Rel.

Authors:  S Sachdev; M Hannink
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

3.  Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.

Authors:  Jarmila Kralova; Andrew S Liss; William Bargmann; Cullen Pendleton; Janani Varadarajan; Emin Ulug; Henry R Bose
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.

Authors:  M You; P T Ku; R Hrdlicková; H R Bose
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  Avian I kappa B alpha is transcriptionally induced by c-Rel and v-Rel with different kinetics.

Authors:  J D Schatzle; J Kralova; H R Bose
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.